These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 29592884)
1. Mechanistic Modeling of Antibody-Drug Conjugate Internalization at the Cellular Level Reveals Inefficient Processing Steps. Durbin KR; Phipps C; Liao X Mol Cancer Ther; 2018 Jun; 17(6):1341-1351. PubMed ID: 29592884 [TBL] [Abstract][Full Text] [Related]
2. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells. Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308 [TBL] [Abstract][Full Text] [Related]
3. Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers. Salomon PL; Reid EE; Archer KE; Harris L; Maloney EK; Wilhelm AJ; Miller ML; Chari RVJ; Keating TA; Singh R Mol Pharm; 2019 Dec; 16(12):4817-4825. PubMed ID: 31609629 [TBL] [Abstract][Full Text] [Related]
4. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates. Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337 [TBL] [Abstract][Full Text] [Related]
5. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies. Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581 [TBL] [Abstract][Full Text] [Related]
6. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design. Dorywalska M; Dushin R; Moine L; Farias SE; Zhou D; Navaratnam T; Lui V; Hasa-Moreno A; Casas MG; Tran TT; Delaria K; Liu SH; Foletti D; O'Donnell CJ; Pons J; Shelton DL; Rajpal A; Strop P Mol Cancer Ther; 2016 May; 15(5):958-70. PubMed ID: 26944918 [TBL] [Abstract][Full Text] [Related]
7. Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization. Harper J; Mao S; Strout P; Kamal A Methods Mol Biol; 2013; 1045():41-9. PubMed ID: 23913140 [TBL] [Abstract][Full Text] [Related]
8. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates. Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707 [TBL] [Abstract][Full Text] [Related]
9. Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63. de Goeij BE; Vink T; Ten Napel H; Breij EC; Satijn D; Wubbolts R; Miao D; Parren PW Mol Cancer Ther; 2016 Nov; 15(11):2688-2697. PubMed ID: 27559142 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy. Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780 [TBL] [Abstract][Full Text] [Related]
11. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics. Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517 [TBL] [Abstract][Full Text] [Related]
12. Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates. Xu S Pharm Res; 2015 Nov; 32(11):3577-83. PubMed ID: 26108878 [TBL] [Abstract][Full Text] [Related]
13. A Bispecific METxMET Antibody-Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes. Perez Bay AE; Faulkner D; DaSilva JO; Young TM; Yang K; Giurleo JT; Ma D; Delfino FJ; Olson WC; Thurston G; Daly C; Andreev J Mol Cancer Ther; 2023 Mar; 22(3):357-370. PubMed ID: 36861363 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. Malik P; Phipps C; Edginton A; Blay J Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691 [TBL] [Abstract][Full Text] [Related]
15. Effect of attachment site on stability of cleavable antibody drug conjugates. Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134 [TBL] [Abstract][Full Text] [Related]
16. Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates. DeVay RM; Delaria K; Zhu G; Holz C; Foletti D; Sutton J; Bolton G; Dushin R; Bee C; Pons J; Rajpal A; Liang H; Shelton D; Liu SH; Strop P Bioconjug Chem; 2017 Apr; 28(4):1102-1114. PubMed ID: 28151644 [TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985. Elgersma RC; Coumans RG; Huijbregts T; Menge WM; Joosten JA; Spijker HJ; de Groot FM; van der Lee MM; Ubink R; van den Dobbelsteen DJ; Egging DF; Dokter WH; Verheijden GF; Lemmens JM; Timmers CM; Beusker PH Mol Pharm; 2015 Jun; 12(6):1813-35. PubMed ID: 25635711 [TBL] [Abstract][Full Text] [Related]
18. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes. Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822 [TBL] [Abstract][Full Text] [Related]
19. Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Kalim M; Chen J; Wang S; Lin C; Ullah S; Liang K; Ding Q; Chen S; Zhan J Drug Des Devel Ther; 2017; 11():2265-2276. PubMed ID: 28814834 [TBL] [Abstract][Full Text] [Related]
20. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)]. Tsuchikama K Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]